Single Inhaler LABA/LAMA for COPD

Overview

Journal Front Pharmacol

Date 2019 May 21

PMID 31105560

Citations 9

Authors

Mario Malerba

Valentina Foci

Filippo Patrucco

Patrizia Pochetti

Matteo Nardin

Corrado Pelaia

Alessandro Radaeli

Affiliations

Soon will be listed here.

Abstract

Chronic obstructive pulmonary disease (COPD) is a common disabling disease characterized by progressive airflow obstruction. Great efforts were spent in the development of drugs able to improve symptoms, quality of life, reduce exacerbations, hospitalizations and the frequency of death of patients with COPD. The cornerstones of treatment are bronchodilator drugs of two different classes: beta agonists and muscarinic antagonists. Currently the Global initiative for COPD suggests the use of long acting beta agonists (LABAs) and long acting muscarinic antagonists (LAMAs) in combination for the majority of COPD patients, thus great interest is associated with the developing of LAMA/LABA fixed combination in the maintenance treatment of stable COPD. Many LAMA/LABA fixed dose combinations have been licensed in different countries and the clinical use of these drugs stimulated the performance of many clinical trials. The purpose of this review is a complete criticism of pharmacological and clinical aspects related to the use of LAMA/LABA single inhalers for the maintenance treatment of stable COPD, with particular mention to the most debated topics and future prospects in the field.

Citing Articles

Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study.

Pelaia C, Ferrante Bannera A, Rotundo F, Tropea F, Armentaro G, Maglio A Int J Chron Obstruct Pulmon Dis. 2023; 18:995-1002.

PMID: 37260547 PMC: 10228585. DOI: 10.2147/COPD.S407238.

Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to-severe COPD.

Salvi S, Jain M, Krishnamurthy S, Balki A, Kodgule R, Tandon M Lung India. 2023; 39(6):517-524.

PMID: 36629230 PMC: 9746267. DOI: 10.4103/lungindia.lungindia_136_22.

Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study.

Salvi S, Kumar A, Agrawal S, Leuva A, Shukla V, Deshpande S Lung India. 2023; 39(5):408-416.

PMID: 36629200 PMC: 9623852. DOI: 10.4103/lungindia.lungindia_92_22.

LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations.

Miravitlles M, Kawayama T, Dreher M J Clin Med. 2022; 11(22).

PMID: 36431099 PMC: 9692772. DOI: 10.3390/jcm11226623.

Mechanisms, Pathophysiology and Currently Proposed Treatments of Chronic Obstructive Pulmonary Disease.

de Oliveira Rodrigues S, da Cunha C, Soares G, Silva P, Silva A, Goncalves-de-Albuquerque C Pharmaceuticals (Basel). 2021; 14(10).

PMID: 34681202 PMC: 8539950. DOI: 10.3390/ph14100979.

References

Newman S, Brown J, Steed K, Reader S, Kladders H . Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest. 1998; 113(4):957-63. DOI: 10.1378/chest.113.4.957. View

Tashkin D, Ferguson G . Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013; 14:49. PMC: 3651866. DOI: 10.1186/1465-9921-14-49. View

Wedzicha J, Decramer M, Ficker J, Niewoehner D, Sandstrom T, Taylor A . Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2014; 1(3):199-209. DOI: 10.1016/S2213-2600(13)70052-3. View

Singh D, Papi A, Corradi M, Pavlisova I, Montagna I, Francisco C . Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016; 388(10048):963-73. DOI: 10.1016/S0140-6736(16)31354-X. View

Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C . Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017; 389(10082):1919-1929. DOI: 10.1016/S0140-6736(17)30188-5. View

Bateman E, Ferguson G, Barnes N, Gallagher N, Green Y, Henley M . Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013; 42(6):1484-94. PMC: 3844137. DOI: 10.1183/09031936.00200212. View

Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L . LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015; 10:1015-26. PMC: 4461092. DOI: 10.2147/COPD.S84436. View

Donohue J, Worsley S, Zhu C, Hardaker L, Church A . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015; 109(7):870-81. DOI: 10.1016/j.rmed.2015.04.018. View

Anderson P . Use of Respimat Soft Mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2007; 1(3):251-9. PMC: 2707154. DOI: 10.2147/copd.2006.1.3.251. View

10.

Salvi S, Brashier B, Gothi D, Karkhanis V, Madas S, Gogtay J . Bronchodilator efficacy of tiotropium-formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD. Pulm Pharmacol Ther. 2013; 27(1):90-5. DOI: 10.1016/j.pupt.2013.05.010. View

11.

DUrzo A, Rennard S, Kerwin E, Mergel V, Leselbaum A, Caracta C . Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2015; 15:123. PMC: 4213545. DOI: 10.1186/s12931-014-0123-0. View

12.

Lal C, Strange C . A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD. Expert Opin Pharmacother. 2017; 18(17):1833-1843. DOI: 10.1080/14656566.2017.1403583. View

13.

Singh D, Worsley S, Zhu C, Hardaker L, Church A . Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm Med. 2015; 15:91. PMC: 4545560. DOI: 10.1186/s12890-015-0092-1. View

14.

Decramer M, Chapman K, Dahl R, Frith P, Devouassoux G, Fritscher C . Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2014; 1(7):524-33. DOI: 10.1016/S2213-2600(13)70158-9. View

15.

Kerwin E, Ferguson G, Sanjar S, Goodin T, Yadao A, Fogel R . Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies. Lung. 2017; 195(6):739-747. DOI: 10.1007/s00408-017-0055-9. View

16.

Singh D, Jones P, Bateman E, Korn S, Serra C, Molins E . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014; 14:178. PMC: 4273456. DOI: 10.1186/1471-2466-14-178. View

17.

Pera T, Penn R . Crosstalk between beta-2-adrenoceptor and muscarinic acetylcholine receptors in the airway. Curr Opin Pharmacol. 2014; 16:72-81. PMC: 4096844. DOI: 10.1016/j.coph.2014.03.005. View

18.

Rodrigo G, Price D, Anzueto A, Singh D, Altman P, Bader G . LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017; 12:907-922. PMC: 5364009. DOI: 10.2147/COPD.S130482. View

19.

Dalby R, Spallek M, Voshaar T . A review of the development of Respimat Soft Mist Inhaler. Int J Pharm. 2004; 283(1-2):1-9. DOI: 10.1016/j.ijpharm.2004.06.018. View

20.

Hanania N, Tashkin D, Kerwin E, Donohue J, Denenberg M, ODonnell D . Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017; 126:105-115. DOI: 10.1016/j.rmed.2017.03.015. View